ICMJE DISCLOSURE FORM

Date: __September_20, _2022 Your Name: __Yasuhide_Yamada

Manuscript Title: _ First-line treatment with nivolumab and chemotherapy for metastatic gastric cancer in East Asia is

not supported by results of the ATTRACTION-4 trial

Manuscript number (if known): _ CCO-22-81

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastChugai	36 months Research grant to the institute, Hamamatsu University School of Medicine
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	_Taiho, Ono,				
	lectures, presentations,	Boehringer-Ingelheim				
	speakers bureaus,	5 5				
	manuscript writing or					
	educational events					
6	Payment for expert	None				
	testimony					
_						
7	Support for attending	None				
	meetings and/or travel					
8	Patents planned, issued or	None				
	pending					
9	Participation on a Data	None				
,	Safety Monitoring Board or	None				
	Advisory Board					
10	Leadership or fiduciary role	None				
	in other board, society,					
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	None				
12	Receipt of equipment,	None				
12	materials, drugs, medical	None				
	writing, gifts or other					
	services					
13	Other financial or non-	None				
	financial interests					
Please summarize the above conflict of interest in the following box:						

The author has received research funding to the institute, Hamamatsu University School of Medicine, from Chugai, and honoraria from Taiho, Ono, and Behringer-Ingelheim.				

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.